The Webinar Series will take place bi-weekly on: Thursdays

12 pm noon (EDT)

9 am (PT), 5 pm (GMT), 6 pm (CET)

We will use a single Zoom webinar registration for the upcoming seminars:

https://dfci.zoom.us/webinar/register/WN_m7JJaw52T8yZYt8-ykL6UQ

Some seminars might be recorded and accessible for a limited time.

 

Upcoming Speakers

April 15th, 2021 

PROTAC Protein Degraders:  A Clinical Update

Webinar registration: https://dfci.zoom.us/webinar/register/WN_m7JJaw52T8yZYt8-ykL6UQ

 

Host: Katherine Donovan

 
 

Debbie Chirnomas

Arvinas

Debbie Chirnomas is the Head of Oncology Clinical Development at Arvinas.  Prior to joining Arvinas, Debbie was VP of Clinical Development and Medical Affairs at Gamida Cell, a cell therapy biotechnology company. Debbie is a pediatric hematologist/oncologist with a specialty in stem cell transplant. She received her medical degree from Albert Einstein College of Medicine, pediatric training at Yale and completed her fellowship at Children’s Hospital Boston/Dana-Farber Cancer Institute. During fellowship, Debbie spent 3 years in the laboratory of Alan D’Andrea and also earned an MPH from Harvard Medical School. Debbie moved back to Yale in 2010 as the Director of the pediatric stem cell transplant program and she continues to maintain a clinical faculty position.

 

During her time there, the clinical team completed a registrational phase 3 randomized trial.  Prior to Gamida Cell, Debbie was at Pfizer where she was part of the team to bring Mylotarg (gemtuzumab ozogamicin) through a successful ODAC to approval in the US and EU. At Pfizer, Debbie also worked on Enzalutamide as part of the Pfizer-Astellas steering committee and the Global Medical Affairs lead participating in the submission, approval and launch of the sNDA indication in non-metastatic CRPC.

Sara Buhrlage

Dana-Farber Cancer Institute

 

April 29th, 2021 

A Chemical Biology Approach to DUBs​

Webinar registration: https://dfci.zoom.us/webinar/register/WN_m7JJaw52T8yZYt8-ykL6UQ

 

Host: Vidyasagar Koduri

Sara Buhrlage, PhD, is an Assistant Professor in Dana-Farber’s Cancer Biology Department and Harvard Medical School’s Biological Chemistry and Molecular Pharmacology Department. Her research group focuses on the development of first-in-class inhibitors and prototype drugs for deubiquitylating enzymes (DUBs) that can be utilized to pharmacologically validate members of the gene family as new targets for cancer treatment and other diseases. DUBs have garnered significant attention recently as potential therapeutic targets in the field of oncology due to their removal of degradative ubiquitin marks from cancer causing proteins.

 

Prior to joining as a faculty member in July 2015, Dr. Buhrlage was a professional track scientist at Dana-Farber in the medicinal chemistry core laboratory. In this role she collaborated with Institute researchers to pharmacologically validate novel targets of disease and study mechanisms of oncogenesis and drug resistance.

 

Dr. Buhrlage completed a Doctor of Philosophy in organic chemistry in 2008, under the direction of Professor Anna Mapp, PhD, from the University of Michigan, where she successfully designed, synthesized and characterized small molecules that bind the transcriptional co-activator CBP and upregulate transcription when tethered to DNA. Following completion of her Doctor of Philosophy, Dr. Buhrlage trained for two years in medicinal chemistry at the Broad Institute.

 
 

Georg Winter

CeMM Research Center for Molecular Medicine

May 13th, 2021 

Identification and characterization of molecular glue degraders

Webinar registration: https://dfci.zoom.us/webinar/register/WN_m7JJaw52T8yZYt8-ykL6UQ

 

Host: Mikolaj Slabicki

 
 

Georg Winter performed his PhD studies with Giulio Superti-Furga, working on elucidating the mechanism of action of anti-neoplastic drugs. He continued his training in chemical biology, working as a postdoc with James Bradner at the Dana Farber where he developed the first generalizable pharmacologic solution to in vivo target protein degradation via phthalimide-conjugation. He was recruited as a CeMM PI in 2016 where his research is focused on deploying targeted protein degradation to understand and disrupt fundamental principles of gene control in cancer. His interdisciplinary research lab is supported by several national and international grants and fellowships including an ERC Starting Grant. Dr. Winter’s contribution to the field of targeted protein degradation was acknowledged via multiple prices and awards, including the Eppendorf Award 2019 and the Elisabeth Lutz Award of the Austrian Academy of Sciences.

TBA

TBA

 

May 27th, 2021 

TBA​

Webinar registration: https://dfci.zoom.us/webinar/register/WN_m7JJaw52T8yZYt8-ykL6UQ

 

Host: 

 
 

TBA

TBA

 

June 10th, 2021 

TBA​

Webinar registration: https://dfci.zoom.us/webinar/register/WN_m7JJaw52T8yZYt8-ykL6UQ

 

Host: